Fox Run Management L.L.C. Takes Position in Zoetis Inc. $ZTS

Key Points

• Fox Run Management acquired 29,511 Zoetis shares worth approximately $2.12 million in the second quarter, making the company about 0.4% of its portfolio. Institutional investors and hedge funds collectively own 92.8% of Zoetis.
• Zoetis reported quarterly EPS of $1.87, slightly exceeding analyst expectations, while revenue of $2.47 billion fell short of estimates and declined 0.2% year over year. The company guided to fiscal 2026 EPS of $6.15–$6.25.
• Shares opened at $73.64, near their 52-week low of $71.45, amid analyst price-target cuts; the consensus rating is Hold with an average target of $109.62. Zoetis also declared a quarterly dividend of $0.53 per share, yielding about 2.9% annually.

Fox Run Management L.L.C. bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 29,511 shares of the company's stock, valued at approximately $2,121,000. Zoetis makes up about 0.4% of Fox Run Management L.L.C.'s investment portfolio, making the stock its 19th largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. RFG Advisory LLC increased its holdings in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company's stock valued at $215,000 after purchasing an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its holdings in Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company's stock worth $240,000 after buying an additional 86 shares in the last quarter. Financial Engines Advisors L.L.C. boosted its holdings in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company's stock worth $299,000 after buying an additional 87 shares in the last quarter. Physician Wealth Advisors Inc. grew its position in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company's stock worth $73,000 after buying an additional 91 shares during the period. Finally, Smithfield Trust Co grew its position in Zoetis by 4.2% during the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company's stock worth $290,000 after buying an additional 92 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE ZTS opened at $73.64 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company's 50-day moving average price is $76.30 and its 200 day moving average price is $99.01. Zoetis Inc. has a 52 week low of $71.45 and a 52 week high of $160.48. The stock has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 1.31 and a beta of 0.74.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. During the same quarter in the previous year, the business posted $1.76 earnings per share. The firm's quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis's dividend payout ratio (DPR) is 34.93%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research reports. Citigroup reduced their price target on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research report on Tuesday. William Blair restated a "market perform" rating on shares of Zoetis in a report on Thursday, August 6th. JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. HSBC dropped their price objective on Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research note on Monday, July 6th. Finally, Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of "Hold" and an average target price of $109.62.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source